Format

Send to

Choose Destination
Alzheimers Dement. 2015 Aug;11(8):933-45. doi: 10.1016/j.jalz.2015.02.005. Epub 2015 Apr 4.

Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.

Author information

1
Department of Neurology, Philipps-University, Marburg, Germany.
2
Eli Lilly and Company Limited, Lilly Research Centre, Windlesham, Surrey, UK.
3
Eli Lilly and Company Limited, Lilly Research Centre, Windlesham, Surrey, UK. Electronic address: reed_catherine@lilly.com.
4
Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.
5
RICE - The Research Institute for the Care of Older People, The RICE Centre, Royal United Hospital, Bath, UK.
6
Agencia Qualitat i Avaluació Sanitaries, Barcelona, Spain.
7
Clinica della Memoria, Department of Neurological Sciences, University of Rome "Sapienza", Rome, Italy.
8
Gerontopole, Alzheimer's Disease Research and Clinical Center, INSERM 1027, Toulouse University Hospital, Toulouse, France.
9
Parc Santari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.

Abstract

BACKGROUND:

To identify the main factors associated with societal costs of Alzheimer's disease (AD) in community-dwelling patients across three European countries.

METHODS:

Baseline cost data from a prospective, observational study were used. Assessments included patients' cognition, activities of daily living (ADLs) and behavioral symptoms, and caregiver burden. Cost calculations (2010) from the societal perspective were based on patient/caregiver resource use. Generalized linear models estimated factors associated with costs.

RESULTS:

Mean monthly costs per patient differed for France (€1881), Germany (€2349), and the UK (€2016), with informal care costs accounting for 50% to 61%. Independent factors associated with costs across all countries were ADL total score, patient living arrangements, caregiver working status, and caregiver burden (all P < .05). Additional factors were significant for the pooled cohort or individual countries.

CONCLUSIONS:

Several patient and caregiver factors, including factors associated with informal care, should be included when evaluating care options for patients with AD.

KEYWORDS:

Alzheimer's disease; Cost of illness; Dementia; Factors; Health care costs

PMID:
25846298
DOI:
10.1016/j.jalz.2015.02.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center